$REGN

AI Analysis

Generated on May 11, 2026

AI Score
78/ 100
Buy$REGN

Regeneron Pharmaceuticals

$REGNNASDAQHealthcareLarge-Cap

Regeneron discovers, develops, and commercializes medicines for serious diseases including Dupixent and Eylea.

Market Cap
$115.0B
Revenue (TTM)
$13.8B
+6.0%
Net Income (TTM)
$4.4B
+8.0%
EPS (TTM)
$40.00
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$750-$1050
Beta
0.32
Dimension Scores
Fundamental
80
Technical
72
Sentiment
76
Risk / Reward
78
Momentum
72
FundTechSentRiskMome
Financial Health
Profitability
85strong
Growth
75strong
Liquidity
86strong
Solvency
82strong
Efficiency
78strong

Valuation, technical analysis, investment thesis, risk assessment and more for $REGN

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.